ESR1 and breast cancer: However, although the acquisition of mutations in ESR1 was observed in 25–40% of the patients with advanced HR+/HER2− BC that progressed under ET, particularly with AIs [193,194], ctDNA analysis from patients enrolled in PALOMA-3 revealed a limited predictive value of ESR1 mutations [151,152].